Medtech and COVID-19: 7 things you need to know (Medical Design & Outsourcing)
When COVID-19 set upon the U.S. in March, medtech executives only had a month at most to explain to analysts in quarterly calls how the pandemic was hitting their companies — not nearly enough time to understand the long-term impact.
Three more months have passed since those quarterly calls, and we’re now wrapping up a new earnings season. While no one can be 100% sure what the future will hold, medtech executives’ comments — and their companies’ actions — are shedding some light on changes coming to the medtech industry.
Here are seven insights we’ve gleaned at Medical Design & Outsourcing and MassDevice from the latest medtech earnings season.
7. Medtech companies are burying the hatchet
Abbott (NYSE:ABT) and Edwards Lifesciences (NYSE:EW) recently settled all outstanding patent disputes related to transcatheter mitral and tricuspid repair products. Two major insulin pump makers — Medtronic (NYSE:MDT) and Tandem Diabetes Care (NSDQ:TNDM) —have inked a non-exclusive patent cross-license agreement related to diabetes treatm...
